Ignite Creation Date:
2024-05-06 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05681715
Status:
COMPLETED
Last Update Posted:
2024-05-23
First Post:
2023-01-04
Brief Title:
A Phase 3 Open-label Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis gMG
Sponsor:
UCB Biopharma SRL
Organization:
UCB Pharma
Organization Data
Organization:
UCB Pharma
Class:
INDUSTRY
Study ID:
MG0020
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
UCB Biopharma SRL
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None